Tokai Pharmaceuticals, Inc., a Cambridge, Massachusetts-based biopharmaceutical company focused on developing new treatments for prostate cancer, raised $35.5m in a Series E financing.
Backers included Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors.
The company intends to use the funds to advance galeterone (TOK-001), its lead prostate cancer drug candidate in patients with castration-resistant prostate cancer (CRPC) and prepare for registration studies.
Tokai Pharmaceuticals is led by Jodie Morrison, CEO.
FinSMEs
15/05/2013